C ytochrome P450 (CYP) 1B1, a member of the CYP enzyme family I, subfamily B, polypeptide 1, that was cloned in 1994 1 is expressed in several nonhepatic tissues including the cardiovascular system. 2 In blood vessels, CYP1B1 is expressed primarily in vascular smooth muscle cells (VSMCs) with very low expression in endothelial cells, and it is increased by shear stress.
C ytochrome P450 (CYP) 1B1, a member of the CYP enzyme family I, subfamily B, polypeptide 1, that was cloned in 1994 1 is expressed in several nonhepatic tissues including the cardiovascular system. 2 In blood vessels, CYP1B1 is expressed primarily in vascular smooth muscle cells (VSMCs) with very low expression in endothelial cells, and it is increased by shear stress. 3, 4 However, CYP1B1 is also expressed in retinal endothelial cells, where it is involved in angiogenesis in response to hypoxia. 5 CYP1B1 is constitutively active and can metabolize several substrates including fatty acids, steroids, and retinoids. 6, 7 CYP1B1 also metabolizes procarcinogens, polycyclic aromatic hydrocarbons, that promote development of tumors and atherosclerosis 8, 9 and result in formation of DNA adducts in VSMCs. 10 Previous studies from our laboratory have shown that CYP1B1 contributes to hypertension and associated pathogenesis, including activation of nicotinamide adenine dinucleotide phosphate oxidase and generation of reactive oxygen species (ROS), inflammation, and endothelial dysfunction in various experimental animal models. [11] [12] [13] [14] We have also shown that VSMC migration, proliferation, and hypertrophy caused by angiotensin II (Ang II) are mediated by CYP1B1-dependent production of ROS.
inflammatory disorder initiated by injury to the endothelium and associated with hypertension, diabetes mellitus, hyperlipidemia, and smoking. Endothelial cell damage promotes adhesion of monocytes, which migrate in the subendothelium where they become macrophages. [16] [17] [18] ROS produced by macrophages and smooth muscle cells oxidize low-density lipoproteins (LDL) into oxidized LDL, which accumulates in macrophages and results in formation of specialized foam cells that give the appearance of yellow color fatty streaks or plaques. [16] [17] [18] Cytokines produced by inflammatory, endothelial, and smooth muscle cells stimulate migration and proliferation of VSMCs that form fibrous caps covering fatty streaks. [16] [17] [18] Because CYP1B1-dependent pathological events in animal models of hypertension (including ROS production, endothelial dysfunction, and inflammation [11] [12] [13] [14] ) are also observed in atherosclerosis, [16] [17] [18] it led us to hypothesize that atherosclerosis and associated pathogenesis caused by hyperlipidemia are mediated by a CYP1B1-dependent alteration in lipid levels and oxidative stress. To thoroughly test this hypothesis, we investigated the effect on the development of atherosclerotic aortic lesions (AAL) and associated pathogenesis including hypertension and the underlying mechanism of the selective CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS), 19 and Cyp1b1 gene disruption in ApoE knockout mice (ApoE −/− ) fed a normal diet (ND) or atherogenic diet (AD). The results showed that CYP1B1 is essential for increased plasma lipid levels, development of AAL, vascular damage, and hypertension in ApoE −/− mice fed AD, most likely by increased oxidative stress independent of lipid absorption. 
Methods

/Cyp1b1
+/+ mice on AD were injected with CYP1B1 inhibitor, TMS (300 µg/kg, IP), or its vehicle (dimethyl sulfoxide, 30 µL) every third day. Aortas were isolated for histological and immunohistochemical characterization of atherosclerotic lesions. Plasma levels of lipids were measured. A separate series of experiments was performed to determine the absorption/production of lipids. Detailed experimental methods are available in the online-only Data Supplement.
Statistical Analysis
Data were analyzed by 1-way ANOVA, and the difference between groups was determined using Newman-Keul's post hoc test for multiple comparisons or Student t test for comparison of 2 groups. The average values of different parameters from 3 to 5 different experiments were expressed as the mean±SEM. P<0.05 was considered statistically significant. Figure S1 in the online-only Data Supplement).
Results
CYP1B1 Inhibitor TMS or
TMS Reduced CYP1B1 Activity Without Altering Its Protein Expression in the Heart
The activity of CYP1B1 and its expression were measured in the heart because of limited amount of aorta available. Cardiac activity of CYP1B1 was increased by AD when compared with ND in ApoE
. Treatment of mice with TMS but not its vehicle dimethyl sulfoxide inhibited cardiac CYP1B1 activity. None of the treatments altered cardiac expression of CYP1B1 protein in these mice ( Figure S2 ). 
TMS or
/
Cyp1b1
+/+ mice on AD, the total collagen content and number of elastin breaks in aorta were increased when compared with mice on ND. Treatment with TMS suppressed collagen content (Figure 2A and 2B) and prevented elastin breaks ( Figure  3A and 3B). In ApoE −/−
/Cyp1b1
−/− mice fed AD, aortic collagen content remained unaltered (Figure 2A and 2B), and breaks in elastin fibers were minimized ( Figure 3A and 3B). 
TMS or
/Cyp1b1
−/− mice, AD had no effect on endothelium-dependent or endothelium-independent dilation ( Figure  S7A and S7B). In ApoE
+/+ control mice fed AD, aortic endothelial function was impaired, as demonstrated by reduced dilation in response to acetylcholine; this impairment was prevented by TMS treatment ( Figure S7C ). Endotheliumindependent dilation, measured by the relaxation of aorta in response to sodium nitroprusside, was not altered in ApoE
+/+ mice fed ND or AD with or without TMS ( Figure  S7D ). No reduction in endothelium-dependent dilation was observed in ApoE
−/− mice fed AD ( Figure S7E ); endothelium-independent dilation was also unchanged in these mice ( Figure S7F ). 
AAL Were Independent of Increase in SBP in
/Cyp1b1
+/+ mice on AD were the result of increased SBP, these mice were placed on drinking water containing a direct vasodilator, hydralazine (125 mg/L), or its vehicle for 12 weeks. The mice were maintained on AD and SBP was measured every fourth week. In ApoE
+/+ mice on AD treated with vehicle, SBP was significantly increased and was associated with the development of AAL. However, in mice given hydralazine, the SBP increase was prevented, but these mice exhibited the same degree of AAL as did the vehicle-treated mice ( Figure S8 ). (ApoE −/− /Cyp1b1 −/− ) fed AD significantly reduced the plasma levels of these lipids, except high-density lipoprotein (Table) . The body weight in the different treatment groups measured at the 12th week before euthanizing the animals was not different (Table) . mice on AD was because of increase in uptake by the liver, decreased absorption, or production of lipids, we determined the liver triglyceride levels, fecal lipid contents, ratio of absorbable and nonabsorbable fat, and secretion of lipids from the liver and gut. Liver triglyceride levels were not altered in ApoE −/−
TMS or Cyp1b1 Gene Disruption Minimized the Increase in Plasma Lipid Levels in ApoE
TMS or Cyp1b1 Gene Disruption Did Not Alter Absorption/Production of Lipids in ApoE
/Cyp1b1
+/+ mice fed AD when compared with those fed ND and remained unchanged by either treatment with TMS or in ApoE −/−
−/− mice fed AD (Table) . The food intake in ApoE −/−
+/+ and in ApoE −/− /Cyp1b1 −/− mice fed ND was higher than in those fed AD because of higher caloric content, but the total fecal lipid contents measured over a period of 72 hours were markedly increased in mice fed AD when compared with those fed ND. The fecal lipid contents were not altered in ApoE
+/+ mice treated with TMS or in ApoE
−/− mice fed AD. None of these treatments altered body weight as measured in these mice over the same 72-hour period (Table S1 ).
The absorption of fat measured by the noninvasive method of determining the ratio of well-absorbed (coconut butter oil) and poorly absorbed fats (olestra; calcium soaps) containing 5% sucrose polybehenate as the marker in the diet and feces was not altered by TMS in ApoE
−/− mice fed AD (Table S1 ). The secretion of lipids from the liver or gut or both as an indirect index of production/absorption of lipids was also determined by measuring plasma triglyceride levels after administering lipoprotein lipase and hepatic lipase inhibitor, proloxamer 407 (P-407) 20 with and without administering peanut oil by gavage in animals fasted for 12 hours (Methods in the Online Data Supplement). Two hours after administering P-407, the plasma levels of triglycerides were increased and remained elevated after 1 hour in ApoE −/−
+/+ mice. This effect of P-407 (increasing plasma triglyceride levels) was not altered in ApoE 
−/− mice ( Figure S9 ). Triglycerides levels increased 1 hour after administering peanut oil but returned to basal levels during the second hour in ApoE 
+/+ mice, markedly increased triglyceride levels after 2 hours that was significantly greater than with P-407 alone ( Figure S9 ).
Discussion
This study demonstrated that CYP1B1 is critical for the development of AAL, associated inflammation, vascular damage, and hypertension in ApoE −/− mice fed AD, most likely by promoting increased oxidative stress and hyperlipidemia, which seems to be independent of lipid absorption. Eight-week-old ApoE −/−
/Cyp1b1
+/+ mice fed AD but not ND for 12 weeks developed AAL in the descending thoracic and abdominal aorta and in sections of proximal aorta. Our finding, that treatment with TMS, an inhibitor of CYP1B1 activity, 19 for 12 weeks in ApoE
+/+ mice fed AD minimized AAL, suggests that CYP1B1 activity is required for the development of lesions. Although CYP1B1 is constitutively active, AD increased CYP1B1 activity without altering its expression as measured in the heart, whereas TMS inhibited its activity but not its expression. Because CYP1B1 is constitutively active, the increase in its activity by AD that could be because of biochemical modification of this enzyme remains to be determined. Further evidence that CYP1B1 is essential for the development of AAL was our finding that ApoE
−/− mice fed AD for 12 weeks did not exhibit atherosclerotic lesions in the descending and abdominal aorta.
Collagen accumulation and elastin disintegration resulting in breakdown of extracellular matrix are characteristic features of atherosclerosis. 21, 22 In ApoE 
−/− mice on AD, it seems that these effects of AD in ApoE −/−
+/+ mice depend on CYP1B1 activity. It is well established that atherosclerosis is an inflammatory disease and that macrophages and T lymphocytes contribute to the development of AAL. 18 AD suggests that CYP1B1 plays a crucial role in inflammation associated with AAL.
The mechanism by which AD in ApoE −/− /Cyp1b1 +/+ mice produces AAL and associated vascular fibrosis, elastin fiber breakdown and inflammation could result from increased ROS production. ROS generated by nicotinamide adenine dinucleotide phosphate oxidase, lipoxygenase, myeloperoxidase, and xanthine oxidase, and decreased NO has been implicated in the pathogenesis of atherosclerosis. 23 Deletion or inhibition of nicotinamide adenine dinucleotide phosphate oxidase, 24 12/15-lipoxygenase, 25 and myeloperoxidase 26 and xanthine oxidase 27 reduces, whereas long-term inhibition of NO synthesis 28 increases, atherosclerosis in animal models. ROS oxidizes LDL to oxidized LDL resulting in chemotaxis of monocytes. 29 ROS also activates immune cells and causes vascular inflammation. 30 Our demonstration that production of ROS in aorta and plasma levels of thiobarbituric acid reactive substances was increased in ApoE
+/+ mice and minimized in mice treated with TMS, and in ApoE
−/− mice on AD suggests that ROS generated by CYP1B1 contributes to the pathogenesis of atherosclerosis. However, additional studies using high-performance liquid chromatograph are required to confirm the production of CYP1B1-dependent generation of ROS. CYP1B1 is expressed in extrahepatic tissues including VSMCs 15, 31 and macrophages 32 and can metabolize fatty acids, retinoic acid, and steroid hormones. 6, 7, 33 Our previous study in VSMCs showed that CYP1B1 metabolizes arachidonic acid and generates ROS, which by activating ≥1 signaling molecules, stimulates VSMCs migration and proliferation, and increases protein synthesis. 15 Our finding that an increase in thiobarbituric acid reactive substances levels in ApoE
+/+ mice on AD was inhibited by treatment with TMS or by Cyp1b1 gene disruption suggests generation of lipid peroxides by CYP1B1. Whether CYP1B1 also generates isoketals that form protein adducts in dendritic cells that activates immune cells, 34 contributing to the pathogenesis of AAL, remains to be determined. Lipid peroxidation products of arachidonic acid are elevated in carotid AAL of patients with symptomatic cerebrovascular disease. 35 Although there is substantial evidence supporting the role of oxidative stress in the development of AAL in animals, antioxidants have not been found in clinical studies in humans 23 to be effective against atherosclerosis. In view of the different sources of ROS and our paucity of our knowledge on the complex interaction among various oxidants and antioxidant enzyme systems and their substrates, additional studies are required to understand the limited protective effects of antioxidants against atherosclerosis in humans.
In the present study, AAL caused by AD in ApoE
+/+ mice were independent of body weight or SBP because, after 12 weeks, body weight in the different groups was not different. SBP was increased in ApoE ) prevented the increase in SBP and endothelial dysfunction, suggests that CYP1B1 contributes to the rise in SBP and endothelial dysfunction in these mice. Previously, we reported that CYP1B1 contributes to Ang II-induced increase in BP and its associated pathogenesis including endothelial dysfunction in male mice by generating ROS and activating ≥1 signaling molecules. 11 Because Ang II promotes AAL in ApoE −/− mice 36 and angiotensin-converting enzyme or Ang II receptor blockers protect against atherosclerosis, 37, 38 it is possible that Ang II via ROS production could contribute to increased SBP, endothelial dysfunction, and atherosclerosis in ApoE
+/+ mice on AD by a mechanism dependent on CYP1B1. The small increase in SBP produced in ApoE
+/+ mice on ND between 4 and 12 weeks that was not altered by either TMS or Cyp1b1 gene disruption is most likely age related. AAL produced by AD in ApoE
+/+ are unlikely the result of increased SBP because administration of hydralazine >12 weeks prevented increased SBP but not the development of atherosclerotic lesions in these mice. In ApoE −/− /Nos −/− mice on AD or in 24-week-old ApoE −/− mice, hydralazine also decreased BP but did not prevent acceleration of AAL. 39 Because hydralazine stimulates renin release 40 and Ang II promotes atherosclerosis in ApoE −/− mice, 36 we cannot exclude the possibility that activation of the renin-angiotensin system masks the protective effect of hydralazine against AD-induced atherosclerosis. Moreover, whether hydralazine protects against collagen deposition, elastin break or inflammatory cell infiltration associated with AAL in ApoE
+/+ mice on AD remains to be investigated. To determine whether TMS and Cyp1b1 gene disruption reduce AAL by altering lipid metabolism, we measured plasma lipid levels. Our finding that treatment with TMS or Cyp1b1 gene disruption minimized the increase in plasma levels of cholesterol, triglycerides, and LDL in ApoE
+/+ mice on AD suggests that the reduction in the development of AAL in these mice is most likely because of decreased plasma lipid levels. The decrease in plasma lipid levels in ApoE 20 to these mice starved for 12 hours, markedly increased plasma triglyceride levels, and peanut oil given by gavage in mice pretreated with P-407 further increased plasma triglycerides. In both cases, treatment with TMS or Cyp1b1 gene disruption did not alter plasma triglycerides. However, additional studies on the composition of lipids in lymphatic chylomicrons are required to evaluate the contribution of CYP1B1 to the process of lipid disposition. Moreover, the mechanism of the decrease in plasma lipid levels in ApoE −/−
+/+ mice by TMS and Cyp1b1 gene disruption that could result from altered lipoprotein, lipid metabolism, and bile salt production, or distribution of fat in adipose and other tissues and fatty acid oxidation remains to be determined. A recent study showed that Cyp1b1-null mice exhibited altered metabolism including resistance to high-fat diet-induced obesity and metabolic syndrome and reduced hyperlipidemia. 41 However, the molecular mechanisms underlying these metabolic change remain to be elucidated. Moreover, the relationship between CYP1B1 and cycloxygenase, 42, 43 lipoxygenase, 25 and caveolin-1 44, 45 that have also been implicated in atherosclerosis needs to be explored.
In conclusion, this study provides evidence for the novel role of CYP1B1 in the development of atherosclerosis in male ApoE −/−
+/+ mice on AD and its pathogenesis including aortic accumulation of collagen, elastin fiber breaks, and infiltration of F4/80 + macrophages and CD3 + T cells, most likely by increased oxidative stress. Thus, the development of inhibitors of CYP1B1, like TMS, could be useful in treating atherosclerosis and hypertension caused by hypercholesterolemia.
Perspectives
The present study provides significant novel insight into the role of CYP1B1 in the development of atherosclerosis, hyperlipidemia, and associated pathogenesis including hypertension in male ApoE −/−
/Cyp1b1
+/+ mice fed AD. Supporting this conclusion is our findings that a selective inhibitor of CYP1B1, TMS, and Cyp1b1 gene disruption in these mice minimizes aortic lesions and associated pathogenesis. These results suggest that CYP1B1 could be a target for treating atherosclerosis. However, it should be noted that CYP1B1 deficiency causes congenital glaucoma. 46 This is likely because of a developmental abnormality in the eye as a result of no CYP1B1; thus, acute or chronic inhibition of CYP1B1 in adults may not cause increased ocular pressure. Therefore, this possibility needs to be evaluated experimentally for the viability of a CYP1B1 inhibitor in treating atherosclerosis.
